Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

被引：0
|
作者：
Wolisnky, J. S. [1 ]
Brochet, B. [2 ]
Montalban, X. [3 ,4 ]
Naismith, R. T. [5 ]
Manfrini, M. [6 ]
Garas, M. [6 ]
Villoslada, P. [7 ]
Model, F. [6 ]
Hubeaux, S. [6 ]
Kappos, L. [8 ]
Hauser, S. L. [9 ]
机构：
[1] UTHealth, McGovern Med Sch, Houston, TX USA
[2] Univ Bordeaux, Bordeaux, France
[3] Univ Toronto, Div Neurol, Toronto, ON, Canada
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, San Francisco, CA 94080 USA
[8] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P910
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [1] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data
    Wolinsky, J. S.
    Brochet, B.
    Hartung, H. -P.
    Naismith, R. T.
    Airas, L.
    Coutant, K.
    Koendgen, H.
    Manfrini, M.
    Mehta, L.
    Prajapati, K.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 56 - 57
  • [2] Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period
    Wolinsky, J. S.
    Montalban, X.
    Hauser, S. L.
    Model, F.
    Deol-Bhullar, G.
    Garren, H.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 656 - 657
  • [3] Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
    Hauser, Stephen
    Brochet, Bruno
    Montalban, Xavier
    Naismith, Robert
    Wolinsky, Jerry
    Manfrini, Marianna
    Garas, Monika
    Villoslada, Pablo
    Model, Fabian
    Hubeaux, Stanislas
    Kappos, Ludwig
    NEUROLOGY, 2018, 90
  • [4] Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
    Wolinsky, J. S.
    Brochet, B.
    Hartung, H. P.
    Naismith, R. T.
    Airas, L.
    Coutant, K.
    Koendgen, H.
    Manfrini, M.
    Mehta, L.
    Prajapati, K.
    Kappos, L.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [5] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
    Montalban, Xavier
    Wolinsky, Jerry
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Chin, Peter
    NEUROLOGY, 2011, 76 (09) : A319 - A320
  • [6] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
    Fox, Edward J.
    Markowitz, Clyde
    Applebee, Angela
    Montalban, Xavier
    Wolinsky, Jerry S.
    Belachew, Sihbeshih
    Fiore, Damian
    Pei, Jinglan
    Musch, Bruno
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870
  • [7] Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis
    Montalban, X.
    Hemmer, B.
    Rammohan, K.
    Giovannoni, G.
    de Seze, J.
    Bar-Or, A.
    Arnold, D.
    Sauter, A.
    Leppert, D.
    Chin, P.
    Garren, H.
    Messier, M.
    Wolinski, J.
    Kakarieka, A.
    Masterman, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 706 - 706
  • [8] Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis
    Wolinsky, Jerry S.
    Kappos, Ludwig
    Montalban, Xavier
    Model, Fabian
    Mehta, Lahar
    Hubeaux, Stanislas
    Giovannoni, Gavin
    NEUROLOGY, 2019, 92 (15)
  • [9] Reduction in 48-Week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
    Wolinsky, J. S.
    Kappos, L.
    Montalban, X.
    Model, F.
    Mehta, L.
    Hubeaux, S.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 322 - 322
  • [10] Effect of Ocrelizumab on Relapse Rate, and Disability Progression and Improvement in Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled OPERA Trials
    Brochet, B.
    Hauser, S. L.
    Montalban, X.
    Naismith, R.
    Wolinsky, J. S.
    Manfrini, M.
    Garas, M.
    Julian, L.
    Villoslada, P.
    Model, F.
    Hubeaux, S.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 322 - 322
12345